Earth Science Tech has uplisted to the OTCQB Venture Market, a premier public market that provides investors with a trusted…
VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies. The…
A new study has found that the risk of people developing sepsis, meningitis or pneumonia as a result of exposure…
Scientists have been struggling to understand why more people who are less than 55 years of age are being diagnosed…
For decades, lots of American patients have been traveling to “fringe” countries like Turkey, Cuba and Thailand in search of…
VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities. Its proprietary BiTAC platform…
Earth Science Tech held its first annual meeting of stockholders, virtually, on August 31, 2026+ The shareholders authorized the Board…
As more Americans become underinsured or uninsured as a result of rising health insurance premiums and the several changes that were passed in…
Researchers across the field, from Duke University to Mayo Clinic, are increasingly focused on restoring damaged cartilage rather than simply…
BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none…